Dosing considerations in the use of the direct oral anticoagulants in the antiphospholipid syndrome
Authors:
- 27 June 2017
- journal article
- research article
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 43 (1) , 104-106
Abstract
At least four prospective trials have been initiated investigating the direct oral anticoagulants in the antiphospholipid syndrome. Preliminary reports have supported their use in patients with a history of venous thrombosis and a target INR of 2-3, but there have also been reports of failure of these agents in the antiphospholipid syndrome. The objective is to present a case report that illustrates there may be important dosing issues when considering the use of these agents in patients with the antiphospholipid syndrome. A 50-year-old woman with the antiphospholipid syndrome, manifesting clinically with recurrent pyoderma gangrenosum-like leg ulcers, was treated with apixaban, resulting in improved ulcer healing. For insurance purposes, she was switched to rivaroxaban with worsening of the ulcers which again improved when apixaban was resumed. Despite a similar half-life, pharmacokinetics and pharmacodynamics, the manufacturer-recommended maintenance dosing of apixaban is twice daily and rivaroxaban once daily. We believe this difference in recommended dose accounts for the differential clinical response noted in the present case report and that twice daily dosing and a larger daily dose of these agents may be more efficacious in potent hypercoagulable disorders, such as the antiphospholipid syndrome.Keywords
This publication has 14 references indexed in Scilit:
- Emerging therapeutic uses of direct-acting oral anticoagulants: An evidence-based perspectivePharmacological Research, 2017
- Optimal dosing of rivaroxaban is undefinedBMJ, 2016
- Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trialThe Lancet Haematology, 2016
- Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndromeRheumatology, 2016
- Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight casesClinical Rheumatology, 2015
- New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndromeAmerican Journal of Hematology, 2014
- Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factorXa inhibitor, in healthy subjectsBritish Journal of Clinical Pharmacology, 2013
- Dramatic Response of Severe Headaches to Anticoagulation in a Patient With Antiphospholipid SyndromeJCR: Journal of Clinical Rheumatology, 2007
- Neurological Dysfunction Associated with Antiphospholipid Syndrome: Histopathological Brain Findings of Thrombotic Changes in a Mouse ModelJournal of Immunology Research, 2004
- Skin Ulcers Misdiagnosed as Pyoderma GangrenosumNew England Journal of Medicine, 2002